|Bid||200.00 x 800|
|Ask||270.27 x 1100|
|Day's range||217.91 - 225.34|
|52-week range||205.10 - 305.21|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||54.19|
|Earnings date||15 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Nov 2012|
|1y target est||320.75|
IRVINE, Calif., January 18, 2022--An abstract presented at STA found that Masimo SET® pulse oximetry had no clinically significant bias based on ethnicity for black or white subjects.
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.
IRVINE, Calif., January 11, 2022--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 1, 2022 and provided estimates for its full-year 2022 financial guidance.